EPS for OncoSec Medical Inc (ONCS) Expected At $-0.23

September 17, 2017 - By Richard Conner

 EPS for OncoSec Medical Inc (ONCS) Expected At $ 0.23

Wall Street await OncoSec Medical Inc (NASDAQ:ONCS) to release earnings on October, 12. Analysts forecast EPS of $-0.23, up exactly $0.16 or 41.03 % from 2014’s $-0.39 EPS. After posting $-0.22 EPS for the previous quarter, OncoSec Medical Inc’s analysts now forecast 4.55 % negative EPS growth. The stock decreased 3.03% or $0.03 on September 15, reaching $0.96. About 115,091 shares traded or 1.38% up from the average. OncoSec Medical Inc (NASDAQ:ONCS) has declined 34.57% since September 17, 2016 and is downtrending. It has underperformed by 51.27% the S&P500.

OncoSec Medical Inc (NASDAQ:ONCS) Ratings Coverage

Among 4 analysts covering OncoSec Medical (NASDAQ:ONCS), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. OncoSec Medical had 7 analyst reports since March 9, 2016 according to SRatingsIntel. As per Thursday, June 8, the company rating was maintained by Maxim Group. Rodman & Renshaw reinitiated it with “Buy” rating and $6 target in Thursday, July 21 report. The stock has “Buy” rating by H.C. Wainwright on Monday, June 12. The stock has “Buy” rating by H.C. Wainwright on Friday, June 2. The rating was maintained by Noble Financial with “Buy” on Tuesday, June 13. The stock of OncoSec Medical Inc (NASDAQ:ONCS) has “Buy” rating given on Wednesday, March 9 by H.C. Wainwright. The stock has “Buy” rating by Maxim Group on Friday, June 2.

OncoSec Medical Incorporated is a biotechnology company. The company has market cap of $20.32 million. The Firm is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. It currently has negative earnings. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation.

More notable recent OncoSec Medical Inc (NASDAQ:ONCS) news were published by: Seekingalpha.com which released: “Inovio Pharmaceuticals And OncoSec Medical: Putting The Pieces Together” on December 15, 2015, also Quotes.Wsj.com with their article: “OncoSec Medical Inc.” published on May 06, 2011, Prnewswire.com published: “OncoSec Medical Appoints Richard B. Slansky as Chief Financial Officer” on June 25, 2015. More interesting news about OncoSec Medical Inc (NASDAQ:ONCS) were released by: Prnewswire.com and their article: “OncoSec Medical’s Intratumoral Plasmid IL-12 Demonstrates Effectiveness at …” published on March 21, 2017 as well as Marketwatch.com‘s news article titled: “0.95” with publication date: May 05, 2011.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.